nach oben

Erschienen in:

01.03.2009 | Original Article

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

verfasst von: Byeong-Bae Park, Ji Eun Uhm, Eun Yoon Cho, Yoon La Choi, Sang Hoon Ji, Do Hyun Nam, Jung Il Lee, Won Park, Seung Jae Huh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We conducted this study to analyze clinicopathologic features and treatment outcomes for various treatment modalities in breast cancer patients with brain metastases.

Patients and methods

Retrospective analysis was performed using medical records of patients who were diagnosed with metastatic brain tumors from breast cancer. The treatment modalities applied included whole-brain radiotherapy (WBRT), surgical resection, stereotactic radiosurgery (SRS) and systemic treatments such as chemotherapy and endocrine therapy.

Results

Among 125 female breast cancer patients with brain metastases, 87.2% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2. The median overall survival (OS) was 6.6 months (95% CI 3.9–9.2). A multivariate analysis using the Cox-regression test identified three risk factors; poor PS (P = 0.023), HER2 positivity (P = 0.013), and no additional systemic treatment (P = 0.006). Those patients who had no risk factors showed outstanding outcome (median OS 49 months). On the contrary, the patients who had all risk factors (poor PS with HER2 positive and did not receive additional systemic chemotherapy) showed dismal prognosis (median OS 2 months).

Conclusions

Our new classification according to the suggested risk factors for patients with metastatic brain tumor from breast cancer reflects particular characteristics of each subset of the patients with good prognostic capacity.

Boogerd W, Vos VW, Hart AA, Baris G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15:165–174PubMedCrossRef

Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J (2001) Adjuvant treatment of brain metastases. Semin Surg Oncol 20:50–56PubMedCrossRef

Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349–2354PubMedCrossRef

Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8:398–410PubMedCrossRef

Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81:1109–1112PubMed

Sparrow G, Rubens R (1981) Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin Oncol 7:291–301PubMed

Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL (1981) Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449–453PubMed

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRef

Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMed

10.

Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655PubMedCrossRef

11.

Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E (2008) Factors affecting the prognosis of breast cancer patients with brain metastases. Breast (Epub ahead of print)

12.

Calyton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastses in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643

13.

Shmueli E, Wigler N, Inbar M (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379–382PubMedCrossRef

14.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotype associated with propensity for central nervous systmen metastses. Cancer 107:696–704PubMedCrossRef

15.

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920PubMed

16.

Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P, Hölzel D (2003) Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55:1186–1195PubMed

17.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500PubMed

18.

Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583–590PubMedCrossRef

19.

Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR (1994) The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711–717PubMed

20.

Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617PubMedCrossRef

21.

Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K (2000) Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 46:297–302PubMedCrossRef

22.

Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ (2003) Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol 61:73–80PubMedCrossRef

23.

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedCrossRef

24.

Peacock KH, Lesser GJ (2006) Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 7:479–489PubMedCrossRef

25.

Cockeril S, Stubberfied C, Stables J, Carter M, Guntrip S, Smith K, McKeown S, Shaw R, Topley P, Thomsen L, Affleck K, Jowett A, Hayes D, Willson M, Woollard P, Spalding D (2001) Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and C-erb-B-2. Bioorg Med Chem Lett 11:1401–1405CrossRef

26.

Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, ahmed SB, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL (2007) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammtory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1–7

27.

Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832–839PubMedCrossRef

28.

Boogerd W, Dalesio O, Bais EM, van der Sande JJ (1992) Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69:972–980PubMedCrossRef

Titel: Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?
verfasst von: Byeong-Bae Park
Ji Eun Uhm
Eun Yoon Cho
Yoon La Choi
Sang Hoon Ji
Do Hyun Nam
Jung Il Lee
Won Park
Seung Jae Huh
Yeon Hee Park
Jin Seok Ahn
Young-Hyuck Im
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0779-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?